NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Salvia BioElectronics

Salvia BioElectronics

Private
EindhovenHealthcare & Life Scienceshttps://www.salviabioelectronics.com/

Last Round

Series B

May 27, 2025

Total Funding Raised

$98.43M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Salvia BioElectronics is a medical device company that develops minimally invasive, ultra-thin implantable neuromodulation technology to treat chronic migraines and cluster headaches.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Biotechnology, Clinical Trials

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

implantable neurostimulationneuromodulationchronic migraine treatmentbioelectronic medicinemigraine implantneurostimulation therapymedical devicebioelectronicsFDA breakthrough devicenerve stimulationmedtechimplantable techbrain-computer interfaceBCI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Salvia BioElectronics Comps

Public and private peers based on sector, stage, and business model.

Salvia BioElectronics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Salvia BioElectronics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series BMay 27, 2025
DebtSep 22, 2020
Series ASep 22, 2020
SeedMay 23, 2018

Key People

Founding team and executive leadership

Daniel Schobben

Chief Operating Officer Founder

Founding Team

Hubert Martens

CEO Founder

Founding Team

Jeroen Siemes

Chief Financial Officer

Executive Team

Salvia BioElectronics Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 25, 2026

    Grew 16% QoQ, from 67 to 78 employees.

  • Apr 23, 2026

    Neuromodulation therapy for chronic migraine is currently being evaluated in clinical studies.

Salvia BioElectronics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Salvia BioElectronics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Salvia BioElectronics's valuation, stock price, and market status.

Firmographic Details

HeadquartersEindhoven
Employee Range78
Year Founded2017
Last FundingMay 27, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.